Literature DB >> 10759341

Long-term pharmacological treatment of generalized anxiety disorder.

V Mahe1, A Balogh.   

Abstract

Generalized anxiety disorder (GAD) is one of the most common anxiety disorders and has a poor prognosis, although it is often thought to be a minor complaint. This disorder has a chronic course of 5-15 years and longer. Long-term treatment with the commonly used benzodiazepines is controversial because of concerns over tolerance and dependence. We performed a thorough search of the literature for clinical trials of a duration of over 2 months conducted in patients with generalized anxiety disorder in order to identify any successful long-term treatment of this disorder. Only eight long-term reports of studies conducted in well-defined homogeneous groups of patients diagnosed with generalized anxiety disorder were found with the methodology of these studies presenting a number of limiting factors. The results are inconclusive and no reference drug could be identified. In addition, an adequate evaluation of the long-term treatment of GAD has not yet been performed.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10759341     DOI: 10.1097/00004850-200015020-00006

Source DB:  PubMed          Journal:  Int Clin Psychopharmacol        ISSN: 0268-1315            Impact factor:   1.659


  8 in total

1.  Generalized anxiety and panic disorder.

Authors:  Joseph Rabatin; Lynn Buckvar Keltz
Journal:  West J Med       Date:  2002-05

Review 2.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2011-10-27

Review 3.  Generalised anxiety disorder.

Authors:  Christopher K Gale; Jane Millichamp
Journal:  BMJ Clin Evid       Date:  2007-11-20

Review 4.  [Generalized anxiety disorder with comorbidity. Treatment with pregabalin].

Authors:  D Lauer; L Hölzel; M Hornyak
Journal:  Nervenarzt       Date:  2006-11       Impact factor: 1.214

5.  The assessment of generalized anxiety disorder: psychometric validation of the Spanish version of the self-administered GAD-2 scale in daily medical practice.

Authors:  Javier García-Campayo; Enric Zamorano; Miguel A Ruiz; María Pérez-Páramo; Vanessa López-Gómez; Javier Rejas
Journal:  Health Qual Life Outcomes       Date:  2012-09-19       Impact factor: 3.186

6.  Evaluation of anxiolytic activity of the essential oil of the aerial part of Foeniculum vulgare Miller in mice.

Authors:  Miraf Mesfin; Kaleab Asres; Workineh Shibeshi
Journal:  BMC Complement Altern Med       Date:  2014-08-23       Impact factor: 3.659

7.  Aggression directed towards others vs. aggression directed towards the self: clinical differences between intermittent explosive disorder and nonsuicidal self-injury.

Authors:  Gustavo C Medeiros; Liliana Seger-Jacob; Anna K Garreto; Hyoun S Kim; Emil F Coccaro; Hermano Tavares
Journal:  Braz J Psychiatry       Date:  2019-03-07       Impact factor: 2.697

8.  Cultural adaptation into Spanish of the generalized anxiety disorder-7 (GAD-7) scale as a screening tool.

Authors:  Javier García-Campayo; Enric Zamorano; Miguel A Ruiz; Antonio Pardo; María Pérez-Páramo; Vanessa López-Gómez; Olga Freire; Javier Rejas
Journal:  Health Qual Life Outcomes       Date:  2010-01-20       Impact factor: 3.186

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.